Scarica l'app Stockscreener
345.55
0.73%
-2.54
Dopo l'orario di chiusura:
345.00
-0.55
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$348.09
Aprire:
$347.56
Volume 24 ore:
175.77K
Relative Volume:
0.44
Capitalizzazione di mercato:
$10.23B
Reddito:
$417.30M
Utile/perdita netta:
$225.03M
Rapporto P/E:
46.19
EPS:
7.4815
Flusso di cassa netto:
$237.38M
1 W Prestazione:
-6.98%
1M Prestazione:
+4.21%
6M Prestazione:
+32.35%
1 anno Prestazione:
+151.38%
Intervallo 1D:
$344.26
$349.65
Intervallo di 1 settimana:
$340.18
$371.99
Portata 52W:
$137.02
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
345.55 | 10.30B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
KRYS: International expansion and pipeline progress set the stage for multi-product growth - TradingView
Krystal Biotech at Cantor healthcare conference: pipeline gains pace - Investing.com
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - Kalkine Media
Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: Unveiling a 7.47% Potential Upside with Promising Genetic Medicine Innovations - DirectorsTalk Interviews
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com Australia
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com Nigeria
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com Nigeria
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) holder to sell 25,000 founders shares - Stock Titan
Krystal Biotech (KRYS) insider moves to sell 2017 shares in a multimillion-dollar deal - Stock Titan
Krystal Biotech stock steadies as regulatory debate over Vyjuvek intensifies - ad-hoc-news.de
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - The Manila Times
Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference - Quiver Quantitative
A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan
Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth - ad-hoc-news.de
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings And 9.54% Potential Upside - DirectorsTalk Interviews
Krystal Biotech, Inc. (KRYS) Stock Analysis: Discovering a 11% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Krystal Biotech Stock Soars 16% in Three Months: Here's Why - Eastern Progress
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Eastern Progress
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Krystal Biotech Inc (MIL:1KRYS) Stock Price, Trades & News - GuruFocus
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring The 15.87% Upside Potential - DirectorsTalk Interviews
Krystal Biotech Insider Sold Shares Worth $8,227,953, According to a Recent SEC Filing - marketscreener.com
State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS - MarketBeat
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile? - simplywall.st
Krystal Biotech (KRYS) Has a New Rating from RBC Capital - The Globe and Mail
Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Krystal Biotech (KRYS) Director Dino Rossi Sells 25,000 Shares - GuruFocus
Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) Advances 1.2% to $332.27, Holding Ground Above Key SupportAggressive Growth Picks - vinanet.vn
Krystal Biotech (NASDAQ:KRYS) director Dino Rossi sells $8.2m shares - Investing.com Australia
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - The Globe and Mail
RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400 - moomoo.com
KRYS Looks 0.5% Undervalued on GF Value™ - GuruFocus
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says - marketscreener.com
KRYS Initiates Coverage by RBC Capital -- Rating Set to Outperfo - GuruFocus
Krystal Bio wins bullish view at RBC Capital Markets (KRYS) - Seeking Alpha
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More - Yahoo Finance
RBC Initiates Krystal Biotech at Outperform, With $400 Price Target - marketscreener.com
KRYSTAL BIOTECH, INC. : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $400 - Bitget
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):